{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:20:58Z","timestamp":1768587658336,"version":"3.49.0"},"update-to":[{"DOI":"10.1016\/j.clml.2025.03.015","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"reference-count":97,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clml.2025.03.015","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T21:51:35Z","timestamp":1743457895000},"page":"571-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["WITHDRAWN: SOHO State of the Art Updates and Next Questions. Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges, and Therapeutic Strategies"],"prefix":"10.1016","volume":"25","author":[{"given":"Alessandro","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2025.03.015_bib0001","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.26828","article-title":"Atypical chronic myeloid leukemia and myelodysplastic\/myeloproliferative neoplasm not otherwise specified: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Patnaik","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0002","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.1365-2141.1996.396933.x","article-title":"Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome?","volume":"92","author":"Oscier","year":"1996","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.03.015_bib0003","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.clml.2025.03.015_bib0004","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.015_bib0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2025.03.015_bib0006","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.03.015_bib0007","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1097\/HS9.0000000000000497","article-title":"Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia","volume":"4","author":"Fontana","year":"2020","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.clml.2025.03.015_bib0008","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cam4.1946","article-title":"Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia","volume":"8","author":"Faisal","year":"2019","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.clml.2025.03.015_bib0009","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"17","key":"10.1016\/j.clml.2025.03.015_bib0011","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/cncr.33622","article-title":"Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia","volume":"127","author":"Montalban-Bravo","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0012","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.03.015_bib0013","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.03.015_bib0014","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00277-023-05106-8","article-title":"Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia","volume":"102","author":"Sun","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12920-024-02039-7","article-title":"ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of wnt-signaling pathways but have differential isoform usage of RUNX3","volume":"17","author":"Lin","year":"2024","journal-title":"BMC Med Genomics"},{"issue":"13","key":"10.1016\/j.clml.2025.03.015_bib0016","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","article-title":"The role of ASXL1 in hematopoiesis and myeloid malignancies","volume":"76","author":"Asada","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clml.2025.03.015_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.exphem.2016.12.006","article-title":"Polycomb complexes PRC1 and their function in hematopoiesis","volume":"48","author":"Vidal","year":"2017","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2643-3230.BCD-23-0235","article-title":"Human ASXL1-mutant hematopoiesis is driven by a truncated protein associated with aberrant deubiquitination of H2AK119","volume":"5","author":"K\u00f6hnke","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0019","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1038\/s41467-018-05085-9","article-title":"Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis","volume":"9","author":"Asada","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.clml.2025.03.015_bib0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s43018-021-00199-4","article-title":"Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia","volume":"2","author":"Wang","year":"2021","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.03.015_bib0021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.clml.2025.03.015_bib0022","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2025.03.015_bib0023","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"issue":"31","key":"10.1016\/j.clml.2025.03.015_bib0024","doi-asserted-by":"crossref","first-page":"51920","DOI":"10.18632\/oncotarget.17231","article-title":"SETBP1 dysregulation in congenital disorders and myeloid neoplasms","volume":"8","author":"Coccaro","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006683","article-title":"Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies","volume":"13","author":"Acuna-Hidalgo","year":"2017","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0296328","article-title":"The landscape of SETBP1 gene expression and transcription factor activity across human tissues","volume":"19","author":"Whitlock","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0027","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41467-018-04462-8","article-title":"SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub","volume":"9","author":"Piazza","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0028","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/leu.2015.200","article-title":"Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development","volume":"30","author":"Vishwakarma","year":"2016","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.clml.2025.03.015_bib0029","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1182\/blood-2011-10-388710","article-title":"Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10","volume":"119","author":"Oakley","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.015_bib0030","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41375-022-01584-3","article-title":"RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS","volume":"36","author":"Kaisrlikova","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement1","key":"10.1016\/j.clml.2025.03.015_bib0031","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2021-148335","article-title":"ASXL1 Mutation cooperating with RUNX1 Mutation further perturbs the differentiation of neutrophils","volume":"138","author":"He","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0032","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41588-018-0060-9","article-title":"RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells","volume":"50","author":"Guallar","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0033","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s42003-020-01391-5","article-title":"Tet2 at the interface between cancer and immunity","volume":"3","author":"Jiang","year":"2020","journal-title":"Commun Biol"},{"issue":"11","key":"10.1016\/j.clml.2025.03.015_bib0034","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.18632\/oncotarget.749","article-title":"Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"3","author":"Chesnais","year":"2012","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.clml.2025.03.015_bib0035","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1073\/pnas.89.5.1725","article-title":"The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3\u2032 splice site","volume":"89","author":"Fu","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.clml.2025.03.015_bib0036","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 Mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0037","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1074\/jbc.M008794200","article-title":"Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway","volume":"276","author":"Lykidis","year":"2001","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.clml.2025.03.015_bib0038","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.260857","article-title":"Mitochondrial phospholipid metabolism in health and disease","volume":"136","author":"Joshi","year":"2023","journal-title":"J Cell Sci"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0039","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1038\/s41467-020-19721-w","article-title":"ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine","volume":"11","author":"Fontana","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.clml.2025.03.015_bib0040","article-title":"Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage","volume":"8","author":"Fontana","year":"2021","journal-title":"Mol Cell Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0041","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","article-title":"RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0042","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"RAS interaction with PI3K: more than just another effector pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"issue":"12","key":"10.1016\/j.clml.2025.03.015_bib0043","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1038\/s41375-021-01278-2","article-title":"Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia","volume":"35","author":"Carratt","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.03.015_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932608","article-title":"A review of granulocyte colony-stimulating factor receptor signaling and regulation with implications for cancer","volume":"12","author":"Park","year":"2022","journal-title":"Front Oncol"},{"issue":"19","key":"10.1016\/j.clml.2025.03.015_bib0045","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.03.015_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2024.152317","article-title":"Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies","volume":"71","author":"Kim","year":"2024","journal-title":"Ann Diagn Pathol"},{"issue":"19","key":"10.1016\/j.clml.2025.03.015_bib0047","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1074\/jbc.RA118.002417","article-title":"Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation","volume":"293","author":"Zhang","year":"2018","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0048","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/cancers14030839","article-title":"Role of CBL mutations in cancer and non-malignant phenotype","volume":"14","author":"Leardini","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.clml.2025.03.015_bib0049","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.2020006528","article-title":"CBL mutations drive PI3K\/AKT signaling via increased interaction with LYN and PIK3R1","volume":"137","author":"Belizaire","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.03.015_bib0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-024-02429-x","article-title":"Non canonical c-CBL mutations define a specific phenotype of myeloid neoplasia","author":"Guarnera","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2025.03.015_bib0051","first-page":"1424","article-title":"Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia","volume":"139","author":"Awada","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0052","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41467-024-45644-x","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"15","author":"Kewan","year":"2024","journal-title":"Nat Commun. Nat Commun."},{"issue":"9","key":"10.1016\/j.clml.2025.03.015_bib0053","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/leu.2017.195","article-title":"Recurrent cyclin D2 mutations in myeloid neoplasms","volume":"31","author":"Khanna","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.03.015_bib0054","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1080\/10428194.2023.2232495","article-title":"CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases","volume":"64","author":"Iaquinta","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0055","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3324\/haematol.2020.252643","article-title":"CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients","volume":"106","author":"Cassinat","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2025.03.015_bib0056","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.clml.2024.07.013","article-title":"Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: a national analysis","volume":"24","author":"Vardell","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.clml.2025.03.015_bib0057","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1182\/bloodadvances.2023011181","article-title":"Characteristics, primary treatment, and survival of MDS\/MPN with neutrophilia: a population-based study","volume":"7","author":"Klein","year":"2023","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.clml.2025.03.015_bib0058","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.03.015_bib0059","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0060","first-page":"717","article-title":"What's different about atypical CML and chronic neutrophilic leukemia?","volume":"2016","author":"Dao","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.clml.2025.03.015_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101133","article-title":"Atypical CML- the role of morphology and precision genomics","volume":"33","author":"Lasho","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0062","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/hematology.2023000448","article-title":"Atypical CML: diagnosis and treatment","volume":"2023","author":"Breccia","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.clml.2025.03.015_bib0063","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia","volume":"11","author":"Hern\u00e1ndez","year":"2000","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.03.015_bib0064","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1007\/s00277-024-06032-z","article-title":"Distinct clinical profiles and patient outcomes in aCML and CNL","volume":"103","author":"Sun","year":"2024","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.clml.2025.03.015_bib0065","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1182\/bloodadvances.2022008204","article-title":"CNL and aCML should be considered as a single entity based on molecular profiles and outcomes","volume":"7","author":"Carre\u00f1o-Tarragona","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.03.015_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107345","article-title":"Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic\/myeloproliferative neoplasm with neutrophilia","volume":"131","author":"Jain","year":"2023","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0067","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjh.19921","article-title":"Chronic eosinophilic leukaemia-not otherwise specified: clinical features, genomic insight and therapeutic strategies","volume":"206","author":"Costa","year":"2025","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.clml.2025.03.015_bib0068","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1182\/bloodadvances.2024013255","article-title":"Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experience","volume":"8","author":"Tessier","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2025.03.015_bib0069","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/cncr.34616","article-title":"ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia","volume":"129","author":"Shuai","year":"2023","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.clml.2025.03.015_bib0070","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1182\/bloodadvances.2023010722","article-title":"CNL and aCML are prognostically distinct: a large National Cancer Database analysis","volume":"7","author":"Tremblay","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2025.03.015_bib0071","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2025.03.015_bib0072","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/2040620715607416","article-title":"Characteristics and survival of BCR\/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database","volume":"6","author":"Giri","year":"2015","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"10.1016\/j.clml.2025.03.015_bib0073","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.03.015_bib0074","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood-2019-127254","article-title":"Current treatments do not improve the prognosis of patients with Atypical CML and unclassified MDS\/MPN. A Joint report from Fi-LMC, FIM, Gfch and GFM","volume":"134","author":"Julien","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.015_bib0075","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ajh.27321","article-title":"Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management","volume":"99","author":"Szuber","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.03.015_bib0076","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.03.015_bib0077","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bmt.1704686","article-title":"Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0078","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/j.1751-553X.2011.01351.x","article-title":"Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.03.015_bib0079","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.03.015_bib0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.leukres.2018.11.003","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan","volume":"75","author":"Itonaga","year":"2018","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.clml.2025.03.015_bib0081","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.03.015_bib0082","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/1097-0142(19950115)75:2<464::AID-CNCR2820750209>3.0.CO;2-E","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results","volume":"75","author":"Cortes","year":"1995","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0083","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V78.1.205.205","article-title":"Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with ph+ CML and chronic myelomonocytic leukemia. The Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","volume":"78","author":"Martiat","year":"1991","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.03.015_bib0084","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.03.015_bib0085","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.03.015_bib0086","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-14-3100","article-title":"The colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I","volume":"22","author":"Maxson","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2025.03.015_bib0087","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2014","journal-title":"Leuk Res Rep"},{"issue":"10","key":"10.1016\/j.clml.2025.03.015_bib0088","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.19.00895","article-title":"Efficacy of Ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"38","author":"Dao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.03.015_bib0089","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.03.015_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106733","article-title":"MYC overexpression is associated with an early disease progression from MDS to AML","volume":"111","author":"Gajzer","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2025.03.015_bib0091","article-title":"A phase 2 study of Fedratinib in patients with MDS\/MPN and chronic neutrophilic leukemia","author":"Kuykendall","year":"2024","journal-title":"ASH"},{"issue":"5","key":"10.1016\/j.clml.2025.03.015_bib0092","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000525566","article-title":"A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations","volume":"145","author":"Desikan","year":"2022","journal-title":"Acta Haematol"},{"issue":"12","key":"10.1016\/j.clml.2025.03.015_bib0093","first-page":"e414","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated Atypical chronic myeloid leukemia","volume":"7","author":"Khanna","year":"2015","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.clml.2025.03.015_bib0094","article-title":"Could it Be a promising drug to treat Atypical chronic myeloid leukemia?","volume":"14","author":"Elsayed","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0095","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1186\/s12885-022-10073-w","article-title":"The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS\/MPN overlap syndromes","volume":"22","author":"Moyo","year":"2022","journal-title":"BMC Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.03.015_bib0096","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood-2023-181673","article-title":"Preliminary results from a phase 1b dose de-escalation stage of Abnl-Marro 001: an International MDS\/MPN Working Group study","volume":"142","author":"Kishtagari","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.03.015_bib0097","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-023-01476-8","article-title":"A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents","volume":"16","author":"Short","year":"2023","journal-title":"J Hematol Oncol"}],"updated-by":[{"DOI":"10.1016\/j.clml.2025.07.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}},{"DOI":"10.1016\/j.clml.2025.03.015","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:38:48Z","timestamp":1754429928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":97,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2152265025001107"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.015","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.clml.2025.07.014","asserted-by":"object"}],"withdrawal":[{"id-type":"doi","id":"10.1016\/j.clml.2025.03.015","asserted-by":"object"}]},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: SOHO State of the Art Updates and Next Questions. Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges, and Therapeutic Strategies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}